Fibrinogen is the major plasma protein coagulation factor. Low plasma fibrinogen concentrations are therefore associated with an increased risk of bleeding due to impaired primary and secondary haemostasis. Fibrinogen is a classical positive acute-phase reactant protein and is an independent predictor of coronary heart disease events. This review considers available methods for measurement of fibrinogen and makes recommendations as to their appropriate use.
Introduction Biochemistry and clinical relevance of fibrinogen
Fibrinogen is the major plasma protein coagulation factor synthesized in the hepatocyte. Its plasma concentration is 1.5^4.5 g/L when measured as clottable protein and approximately 8.8mmol/L total protein. It is a heterodimeric molecule, with each half containing three di¡erent polypeptide chains (Aa, Bb, and g) which are linked by disulphide bridges. Thrombin cleaves the Aa and Bb chains to release ¢brinopeptides A and B, respectively, from the aminoterminal ends. After ¢brinopeptide release, the resulting ¢brin monomers undergo polymerization to form an insoluble ¢brin clot. 1 Fibrin is subsequently lysed by the endogenous ¢brinolytic system, forming ¢brin degradation products (FDP) (see Fig. 1 ).
While best known as the precursor of ¢brin, ¢brinogen also plays an important role in platelet aggregation by linking activated platelets. Activated platelets express on their surface the integrin /IIb b3 (also known as the activated platelet membrane glycoprotein receptor GP IIb/IIIa), which binds ¢brinogen (from plasma, as well as that secreted from intraplatelet granules following platelet activation). Fibrinogen therefore plays a key role in haemostasis and thrombosis.
Haemostasis is the physiological cessation of blood loss after vessel injury, resulting from interactions between the blood vessel wall, platelets, coagulation and ¢brinolysis. Following vessel injury, circulating platelets are activated by subendothelial collagen and thrombin; activated platelets in turn secrete or synthesize other inducers of platelet aggregation, including adenosine diphosphate (ADP), serotonin and thromboxane A 2 (TxA 2 ). Activated platelets adhere to the injured vessel wall (platelet adhesion) and to each other (aggregation), building up a plateletrich plug which initially secures haemostasis (primary haemostasis). This initial, friable platelet plug is subsequently stabilized by ¢brin formation (secondary haemostasis). Thereafter, the ¢brin plug is digested over several days by the active enzymes of endogenous ¢brinolytic systems (plasmin, neutrophil elastase), in parallel with tissue repair processes.
Low plasma ¢brinogen concentrations are therefore associated with an increased risk of bleeding, due to impaired primary haemostasis (prolonged skin bleeding time in vivo, decreased platelet aggregability in vitro) as well as impaired secondary haemostasis (prolonged blood clotting times: thrombin time, prothrombin time, activated partial thromboplastin time). Some common causes of low ¢brinogen concentrations are listed in Box 1.
Thrombosis is 'haemostasis in the wrong place', resulting from general or local activation of platelets and coagulation. Platelet-¢brin deposition may occur in the microcirculation due to generalized coagulation activation in disseminated intravascular coagulation (DIC), which consumes plasma ¢brinogen and may therefore present as excessive bleeding (see Box 1) . More commonly, platelet-¢brin thrombi occur locally following:
. Rupture of an arterial atherosclerotic plaque (e.g. coronary thrombosis causing acute coronary syndromes, myocardial infarction or sudden cardiac death; aortic, carotid or vertebrobasilar thromboembolism causing transient cerebral ischaemic attacks or ischaemic stroke; peripheral arterial thromboembolism);
. Intracardiac thromboembolism (e.g. atrial ¢brillation, diseased or arti¢cial heart valves);
. Venous thromboembolism (e.g. due to stasis of blood in leg veins following prolonged bedrest or immobilizing travel).
Increased plasma ¢brinogen concentrations have been associated with these thrombotic states as well as with several risk factors for thrombotic disease (see Box 1) . Fibrinogen is also a classical positive acute-phase reactant protein 1,2 and its elevation plays a key role in elevation of haematological measures of the acutephase response, such as plasma viscosity and the erythrocyte sedimentation rate (ESR). 14 Metaanalyses of prospective studies have shown that ¢brinogen, 15, 16 plasma viscosity and ESR 17 are independent predictors of coronary heart disease events. While there are several mechanisms through which increased plasma ¢brinogen concentrations may Reduced fibrinogen 8 Afibrinogenaemia, hypofibrinogenaemia, dysfibrinogenaemia 9 Liver disease Disseminated intravascular coagulation Thrombolytic therapy [10] [11] [12] Defibrinogenation therapy (ancrod) Haemodilution Adapted from reference 13, with permission. promote arterial disease and ischaemic events (including atherogenesis, platelet and ¢brin components of arterial thrombosis, and increased viscosity which promotes ischaemia distal to atherothrombotic stenoses or occlusions), a causal role for plasma ¢brinogen or viscosity in arterial thrombosis remains to be established by large, long-term randomized controlled trials of reducing their variables. At present only certain ¢brate drugs (which have multiple e¡ects on vascular risk factors) lower plasma ¢brinogen, and this e¡ect is small (10-15% reduction). Development of more e¡ective ¢brinogen-lowering agents is required. Meanwhile, the Fibrinogen Studies Collaboration (fsc@medschl.cam.ac.uk) is analysing individual data from prospective studies of plasma ¢brinogen in order to inform further on its predictive value for coronary heart disease and stroke. This topic has recently been comprehensively reviewed. 18 The International Fibrinogen Research Society brings together scientists and clinicians every two years to review and present new data on all aspects of ¢brinogen. The published proceedings of the XVIth International Fibrinogen Workshop held in 2000 19 form a comprehensive review of the biochemical, biological and clinical aspects of ¢brinogen.
Historical perspective of methods
The clinical utility of ¢brinogen assays is summarized in Box 2.
Bleeding risk
Historically, plasma ¢brinogen assays have been performed in the coagulation sections of haematology laboratories, for the investigation, monitoring and treatment of bleeding risk associated with low ¢brinogen concentrations (congenital, pathological or therapeutic). Such assays may be incorporated with clotting time tests in routine 'coagulation screens' or performed selectively in patients with prolonged clotting times (especially the thrombin time, which is most sensitive to ¢brinogen de¢ciency). Rapid, simple routine methods to quantify the plasma concentration of clottable ¢brinogen are required for this purpose. First, such patients often present as acute bleeding emergencies (e.g. major trauma, obstetric complications or DIC), which often occur outside routine laboratory hours and may require frequent repetition. Second, clottable ¢brinogen is believed to be the most clinically relevant measure, given the key function of ¢brinogen in achieving secure secondary haemostasis. For routine investigation, monitoring and treatment of bleeding risk, automated clotting rate assays 20, 21 which measure the clotting time of plasma dilutions are currently preferred for quantitation of low functional (clottable) ¢brinogen assays. 13 Following the development of automated coagulometers which employ optical density or light scatter to detect ¢brin formation as the endpoint in clotting time assays, many haematology laboratories have estimated ¢brinogen concentrations from clotting times, notably the prothrombin time (PT; PT-derived ¢brinogen assay). 22^29 However, such assays have several problems, including: giving higher values than von Clauss assays; 30^37 variation between di¡erent analysers and reagents; and problems of calibration. 13 Most PT-derived assays yield higher values than the clotting rate (von Clauss) techniques in patients with DIC, liver disease, renal disease, dys¢brinogenaemia, high ¢brinogen concentrations, and in those receiving anticoagulant or thrombolytic therapy. The discrepancy is not consistent over the observed range of ¢brinogen values and is particularly marked in dys¢brinogenaemia and thrombolytic therapy. Part of the reason for this may be that ¢brinogen degradation products have no impact on the PT-derived assay but inhibit ¢brin polymerization and therefore prolong the clotting time in the clotting rate assays, yielding lower ¢brinogen values. 38 Since ¢brin polymerization is considered to have pathophysiological relevance, this can be perceived to be a problem with the PT-derived assay. The PT-derived assay is also in£uenced by the analyser, reagent and calibrant used. The measuring range di¡ers depending on the reagent and analyser combination used; this di¡erence has been shown to be as high as 2 g/L, between certain reagents, for samples with elevated ¢brinogen concentrations. Some methods are poorly standardized, with certain analysers only requiring a two-point calibration curve (one of which is not a measured point). Furthermore, Ann Clin Biochem 2004; 41: 430-440 Box 2. Clinical and commercial utility of fibrinogen assays (a) Bleeding risk -Investigation, monitoring and treatment of a haemorrhagic state (afibrinogenaemia, hypofibrinogenaemia, acquired or congenital dysfibrinogenaemia) 9,13 -Investigation of unexpected prolonged or abnormal coagulation tests -Detection, monitoring and treatment of disseminated intravascular coagulation -Establishment and monitoring of prolonged thrombolytic therapy 10-12 -Establishing and monitoring of defibrinogenation therapy (ancrod) (b) Risk assessment profiling for arterial disease (c) Detection of acute-phase reactions (d) Commercial use (diagnostics industry, pharmaceutical industry, blood transfusion service) for quality monitoring and potency assignment (e.g. factor VIII or fibrinogen concentrates).
Adapted from reference 13, with permission.
PT-derived assays are in£uenced by the optical clarity of test plasmas as well as calibrant plasmas 38 and there are problems in some methods with high potency calibrants, which could create di⁄culties when ¢brinogen is measured in cardiovascular risk studies. PT-derived ¢brinogen assays also tend to be less precise than clot rate assays, particularly in patients receiving anticoagulants or with high ¢brinogen concentrations. Prothrombin time-derived ¢brinogen assays are therefore a group of loosely related methods, separated by reagents, analyser technology and calibrant plasmas, and hence are not recommended as routine methods. 13 Not all plasma ¢brinogen is functional (clottable). This is because circulating ¢brinogen shows considerable heterogeneity in structure and function, partly due to multiple genetic in£uences and partly to degradation by enzymes including thrombin, plasmin and neutrophil elastase. 19 Assays of clottable ¢brinogen may therefore give di¡erent results from other ¢brinogen assays, such as immunological assays or heat/salt precipitation assays, which measure 'total' ¢brinogen, whether clottable or not. These assays are inappropriate for the assessment of bleeding risk due to low functional ¢brinogen concentrations. They are useful, however, to distinguish low total ¢brinogen concentrations (a¢brinogenaemia, hypo¢brinogenaemia) from dys¢brinogenaemias (in which clottable plasma ¢brinogen is low but immunological ¢brinogen is normal). Many haematology laboratories therefore routinely use a 'total' immunoassay of ¢brinogen as well as a clottable ¢brinogen assay.
Risk assessment profiling for arterial disease
While most prospective studies of relationships between health and plasma ¢brinogen concentration have used assays of clottable ¢brinogen, 15 some have used immunonephelometry 39 or heat precipitation. 40^43 A meta-analysis has shown no heterogeneity between prospective studies, despite the use of a wide variety of assay types. 15 However, the only direct comparative study to date observed a signi¢cantly stronger predictive value for incident coronary heart disease by a heat-precipitation assay compared with clotting rate von Clauss assays. 42 Further randomized comparisons are required, and the Fibrinogen Studies Collaboration (see above) is also studying the e¡ect of assay type on arterial disease prediction.
Immunological or precipitation assays can be automated and used routinely in biochemistry laboratories as measures of arterial risk prediction (and/or acutephase reactions). For example, immunonephelometry is employed in the BN-100 or Prospec clinical analysers (Dade Behring, Marburg, Germany). Heat precipitation has not been automated, to our knowledge, nor has salt precipitation, e.g. by sulphite. 43 These assays have the practical advantage over clottable ¢brinogen assays that they do not require a citrate sample and can be performed in, for example, dipotassium edetate samples which are used for routine lipoprotein assays in biochemistry laboratories or full blood counts in haematology laboratories.
Commercial uses and reference methods
Therapeutic considerations (bleeding risk from low clottable ¢brinogen) have led commercial concerns and standards development bodies [e.g. National Institute for Biological Standards and Control (NIBSC)] to prefer clottable ¢brinogen assays, especially in potency assessment of ¢brinogen concentrates and of other clotting factor concentrates (e.g. factor VIII and IX concentrates, in which ¢brinogen is a marker of impurity with possible infective, hyperviscosity and immunological risks). Several accurate reference methods have been described. 44^48 Table 1 shows the recommended types of ¢brinogen assay in di¡erent situations. 13 Reference method for total clottable fibrinogen. A variety of methods are available. The European Concerted Action against Thrombosis methodology group 21 recommended the method of Blomba« ck and Blomba« ck. 46 When preparing the First International Fibrinogen Standard, Ga¡ney and Wong 48 used the assay of Jacobsson. 45 Routine, simple, rapid assay of clottable fibrinogen for assessment of bleeding risk associated with low plasma levels. Among currently available routine assays, the clotting rate assay 20 is preferred to the PT-derived assay. 13 Immunoassay of total fibrinogen, to distinguish hypofibrinogenaemias from dysfibrinogenaemias. A variety of immunological assays of total ¢brinogen are available [e.g. radial immunodi¡usion (RID), enzyme-linked immunosorbent assay (ELISA), nephelometry], and there is little direct evidence on comparative performance. Enzyme-linked immunosorbent and immunonephelometric assays are preferred because of higher precision; total clottable ¢brinogen assays may sometimes be useful. 13 Routine assay of fibrinogen for assessment of risk of arterial disease events. Automated clotting assays 20 can be used, but assays of total ¢brinogen may have similar (or superior) predictive value. 42 The automated immunonephelometric assay shows similar predictive value to assays of clottable ¢brinogen 15, 39 and has the advantage of not requiring a citrated plasma sample.
Perspective on currently available procedures
Other fibrinogen assays. These include gravimetric and titration methods 49 which are now obsolete.
Definitive, reference and field methods
As discussed above, the de¢nitive and reference method is total clottable protein. 21, 45, 46, 48 Routine methods include:
. The automated clotting rate assay 20,21 for assessment of bleeding risk associated with low clottable plasma ¢brinogen, and for assessment of risk for arterial disease events; . An immunoassay (ELISA or nephelometric) to distinguish hypo-from dys-¢brinogenaemias; . An automated immunoassay of total ¢brinogen 39 for assessment of risk for arterial disease events, when citrated samples are not available.
Methodology Principles
Total clottable fibrinogen assay (De¢nitive and reference method.) 21, 46 Principle of measurement. Thrombin is added to citrated plasma and during prolonged incubation (in the absence of Ca 2+ ions) converts all ¢brinogen to a ¢brin clot; epsilon aminocaproic acid (EACA) is added to inhibit plasmin degradation of the ¢brin clot (see Fig. 1 ). Soluble proteins trapped within the clot are removed by gentle expression of serum from the clot and by subsequent washing of the clot. The clot may include larger ¢brin degradation products (FDPs) (which increase the assay value); in contrast, FDPs inhibit the rate of conversion of ¢brinogen to ¢brin by thrombin in the von Clauss 20 assay (see Fig. 1 ). Hence, while total clottable ¢brinogen is used to calibrate the von Clauss assay, discrepancies arise in the presence of high plasma FDP concentrations (e.g. during DIC, or thrombolytic or de¢brination therapy; see Box 2).
Detection principle. In the absence of Ca 2+ ions, the clot is not stabilized and remains soluble in concentrated urea solution. The ¢brinogen concentration in g/L can be measured either by tyrosine determination in the well washed clot or more easily by measuring light absorbance at 282 nm. Materials and assay procedures are given in reference 21.
Clotting rate assay 20, 21 Principle of measurement. A standardized, high concentration (*100 U/mL) thrombin solution is added to bu¡er-diluted plasma and the clotting time recorded. The Michaelis-Menten constant K m for the cleavage of the A ! chain by thrombin is about 7mmol/ L, while the normal plasma concentration is approximately 9 mmol/L; therefore the velocity of clot formation is signi¢cantly a¡ected by di¡erent functional ¢brinogen concentrations even within the physiological range. 21 The plasma dilution reduces the in£uence of endogenous and exogenous inhibitors (e.g. antithrombins, heparinoids) but not the retarding e¡ects of FDP (see above). The ¢brinogen concentration in g/L is obtained by comparing the clotting time of the plasma sample with serial dilutions of a reference plasma with known ¢brinogen concentration, according to bioassay principles.
Detection principle. Citrated plasma is diluted 1:10 with bu¡er immediately before adding the thrombin solution. The clotting time is recorded either manually by a tilt-tube technique or using a Kolle hook and a stopwatch, or (more accurately) in an automated coagulometer. The calibration curve is obtained from the clotting times of serial dilutions (1:10, 1:20, 1:30, 1:50) of standard plasma with known clottable ¢brinogen concentration. In the manual method, double logarithmic paper is used to plot times on the ordinate against concentrations (g/L) on the abscissa. The clotting times of diluted test plasma samples are converted to ¢brinogen concentrations. Marbet and Duckert 21 reported a linear calibration curve in an automated coagulometer, and a hyperbolic curve with the manual method. Materials and assay procedures for the manual method are given by Marbet and Duckert. 21 The manual method is time-consuming and requires high technical expertise.
Immunological fibrinogen assays (RID, ELISA and immunonephelometric)
Principle of measurement. In immunonephelometric and RID assays, speci¢c polyclonal antibodies to ¢brinogen are incubated with diluted plasma samples, forming immune complexes. These are detected either by di¡usion and precipitation in an agarose gel (RID) or by light-scattering (nephelometry). In ELISA techniques, ¢brinogen molecules from diluted plasma are captured by speci¢c antibodies immobilized on a polystyrene surface (microplates or tubes). Bound ¢brinogen is detected using a second, enzymeconjugated antibody to ¢brinogen.
Detection principle. In RID, the amount of ¢brinogen is measured in terms of the diameter of a di¡usion ring resulting from the immunoprecipitate. This can be quanti¢ed by reference to serial dilutions of standard plasma with a known ¢brinogen concentration. Immunonephelometric methods require a particular type of analyser that detects the amount of immune complex present, and quanti¢cation is again by reference to the reactivity of dilutions of standard plasma. In ELISAs, the amount of ¢brinogen bound to the plastic surface via the primary antibody is measured in terms of the enzyme-conjugated antibody, which is measured photometrically using a suitable enzyme substrate. The absorbance is therefore proportional to the plasma ¢brinogen concentration, and the system is calibrated by the inclusion of dilutions of a standard plasma in each set of assays.
Sample
Plasma versus other body fluids and tissues. This review is con¢ned to plasma ¢brinogen. Serum is clotted plasma, hence by de¢nition is ¢brinogen-free; this fact does not deter many scientists and clinicians from referring to 'serum ¢brinogen', even in peer-reviewed journals! Whole blood assays have been described, e.g. measurement of the depth of heat-precipitated (568C) ¢brinogen using a light microscope withVernier scale, following centrifugation in a microhaematocrit tube; 51^53 however, they are time-consuming and labour-intensive. Fibrinogen is present in lymph but not in urine or cerebrospinal £uid (CSF) except in pathological states. Assays of ¢brinogen and ¢brin in tissue samples are considered in histopathological texts. Fibrinogen and ¢brin are present in the arterial wall and may play a role in atherosclerosis and arterial thrombosis. 53 Collection and storage conditions for plasma samples are summarized in Table 2 .
The recommended anticoagulant is tri-sodium citrate at a strength of 0.105-0.109 mol/L (one part anticoagulant: nine parts blood), as used for other blood coagulation tests. 54 Inadequate ¢lling of the collection tube a¡ects this ratio and leads to inaccurate results. At haematocrits greater than 0.55 L/L, the ¢nal blood citrate concentration requires adjustment, and charts are available which indicate the amounts of anticoagulant and blood to be mixed. 54 It is essential that blood is collected by clean venepuncture, with minimal stasis and as rapidly as possible. 55 Prior to ¢brinogen determination, blood or plasma samples should be inspected by gentle inversion to detect the presence of clots. Samples with any evidence of clots or marked haemolysis should be rejected. 13 Plasma should be prepared so that platelets are removed (to a count of 510610 9 /L) by centrifugation (minimum 1700 g for 10 min); this can be performed at room temperature. Severely lipaemic or icteric samples may cause analysis di⁄culties in some photooptical methods of ¢brinogen measurement.
Volumes required. The plasma volume required depends on the assay and the characteristics of automated coagulometers (including dead space in sampling systems as well as volume of sample actually tested). The reference method requires 300 mL plasma. 21, 46 Automated coagulometers and nephelometers require about 200 mL plasma (see manufacturers' instructions).
Storage conditions. Plasma samples can be stored at room temperature prior to ¢brinogen determination for at least 4 h and probably longer. If more prolonged storage is required then 48C is a suitable temperature for von Clauss ¢brinogen determination. Storage at 48C for up to 48 h did not a¡ect results in one study. 55 Plasma can be stored deep-frozen for longer periods, 56 preferably at 7708C; as such it is stable for at least 18 months. 57 Storage of samples from patients with DIC, or those receiving thrombolytic or de¢brinogenation (ancrod) therapy, may lead to in vitro proteolysis of ¢brinogen unless suitable protease inhibitors are included in the anticoagulant. 10 Ann Clin Biochem 2004; 41: 430-440 If plasma is frozen prior to analysis it should be immediately transferred to a 378C waterbath, thawed for 5 min at 378C and mixed by inversion prior to analysis. Any slow or partial thaw can lead to the formation of cryo-precipitate (which contains ¢brinogen), a¡ecting the results. For assay of ¢brinogen in therapeutic cryo-precipitate products and other ¢brinogen concentrates, a full thaw at 378C is necessary followed by careful mixing to re-suspend ¢brinogen. This material will normally require greater dilution than normal plasma in order to achieve a concentration that can be successfully assayed by the von Clauss method.
Accuracy

Main causes of inaccuracy
The main causes of inaccuracy are pre-analytical variables (see Table 2 ), discussed in the previous section.
Fibrin degradation products. As noted above ('Methodology', 'Principles'), high plasma concentrations of FDP (e.g. during DIC, thrombolytic therapy or de¢brinogenation therapy) result in overestimation of functional ¢brinogen by the total clottable protein assay (and also by immunological and precipitation assays) and in underestimation of functional ¢brinogen by the clotting rate assay. 10, 20, 21 The latter assay is recommended for patient monitoring in these situations because it is rapid, widely available, shows reasonable inter-laboratory agreement and is probably a more reliable index of haemostatically e¡ective ¢brinogen than other rapid assays. 10, 38 Heparins. High plasma concentrations of heparins also inhibit clotting rate assays.
Analytical sources of inaccuracy. In assays of clottable ¢brinogen these include:
. High ¢brinogen samples (concentrates or plasma samples) which exceed the limits of standard curves (see Table 2 ) and which, in clotting rate assays, may be inaccurate because of short clotting times (accuracy limited to 0.1s); . Dilution control (pipette accuracy); . Temperature control;
. Reagent control (e.g. pH changes due to reagent vial remaining open to the air for prolonged periods); 13 . Standard control. The standard plasma or calibrant must be carefully selected, because very turbid reference plasmas may cause poor linearity on optical coagulometers and poor parallelism with serial dilutions of test plasma. 58 This may lead to incorrect potency assignment, particularly for samples with low ¢brinogen concentrations, when single-point assays are performed. Some commercial reference plasma designed for use in von Clauss assays appear to be erroneously calibrated when compared with the International Standard. This may re£ect the calibration method used by the manufacturer, or the use of calibrants other than the International Standard. 13 Methods of improving accuracy FDP and heparin. Some manufacturers include inhibitors of heparin and FDP in bu¡ers, to reduce the impact of heparin and FDP on clotting rate assays. Where possible, assays should not be performed on samples collected within 4 h of unfractionated heparin administration or samples collected from heparin-contaminated venous or arterial lines. This may be a particular problem during cardiopulmonary bypass or renal dialysis procedures, and in these situations it may be necessary to remove the heparin using suitable ion exchange resins or heparinase enzymes. 13 High-fibrinogen samples. These should be diluted (see Table 2 ).
Reagent control. The reagents in common use in the UK have been evaluated 37 and found to produce only small di¡erences in ¢brinogen concentrations. The reagent must only be used during its stated period of stability, and care should be taken that pH changes do not occur due to the reagent vial remaining open to the air for prolonged periods. If single calibration curves are used for the lifespan of the reagent, it should be ensured that the reagent is still stable and viable for the entire period. Quality-control samples should be used to check for temporal drift. 13 Standard control. An optically clear ¢brinogen standard is desirable to avoid loss of linearity on some analysers. A suitable dilution range must be used (this will vary depending on the calibrant, reagent and analyser), and the calibration curve must be linear (this normally requires logarithmic transformation). The calibration curve must include at least three (but preferably ¢ve) dilutions of the plasma, and duplicate clotting times are advised. Test samples should be rediluted if they are outside the linear range of the assay. A single type of reagent kit, standard and analyser within the laboratory should be used, as the results may not be easily interchangeable between methods. 13 Analyser variation. An evaluation of analysers 37 showed signi¢cant di¡erences, but these are unlikely to have clinical impact (*0.1g/L).
Acceptable degree of inaccuracy
This is tentatively suggested as 0.3 g/L, in terms of clinical treatment decisions.
Imprecision
Clotting rate assay
Reasonable imprecision (inter-batch coe⁄cient of variation) is obtained in coagulometers with normal plasma: typically 3-7% by optical methods and 6-9% by mechanical methods. 21, 38 Manual methods are less precise (10% or above).
Immunoassays
Similar precision to clotting rate assays is obtained with normal plasma for ELISA and immunonephelometric assays (see manufacturers' instruction sheets).
Sensitivity
Lowest detectable amount
This is about 0.3 g/L for clottable ¢brinogen assays, but varies with methods (see manufacturers' instruction sheets). ELISA typically has 41000-fold higher sensitivity.
Lowest quantifiable amount
This is about 0.5 g/L, in clotting rate assays, but varies with methods (see manufacturers' instruction sheets).
Linearity
The upper limit of accepted linearity is typically about 6 g/L for clotting rate assays and about 8 g/L for the immunonephelometric assay. This varies with assay type, reagent and instrument (as discussed above) and should be determined in each laboratory. As noted above, the clotting rate assay is usually linear on a double logarithmic plot. 21 
Calibration Standards
Prior to the development of the First International Fibrinogen Standard (NIBSC First International Standard for Fibrinogen, Plasma), 48 there was a wide variation between commercially available ¢brinogen standards. 59 While this standard (and its successor, the currently available Second International Fibrinogen Standard) 60 have improved the situation, some commercial reference materials appear erroneously calibrated when compared with the International Standard (see above). The First and Second International Standards were calibrated by functional rather than immunological methods. Until a directly calibrated standard becomes available, the same standard should be used for all types of ¢brinogen assay and similar potency assumed. It is essential that the same standard material is used for di¡erent ¢brinogen assays within an individual laboratory, to avoid systematic error. 13 The utility of a high ¢brinogen standard is currently under investigation.
In the UK, the Eighth British Standard for Blood Coagulation Factors, Plasma, Human (NIBSC code 98/ 734) is available (NIBSC, Blanche Lane, South Mimms, Potters Bar, Herts EN6 3QG, UK). It is calibrated for ¢brinogen against the Second International Fibrinogen Standard 60 (plasma 98/612) as well as for other commonly assayed coagulation factors and inhibitors. Vials should be stored unopened at 7208C or below. The contents should be reconstructed with distilled water and kept on ice. The standard is su⁄ciently stable to be used over a 1-2-h period. Unused material may be refrozen for subsequent immunoassays but should not be reused for bioassays.
Local reference plasma may be prepared by pooling plasma from at least six healthy normal donors, and calibrating against National (British Standard for Blood Coagulation Factors, Plasma, NIBSC) or International (Second International Standard for Fibrinogen, Plasma) standards. Ideally, these pools should be stored in aliquots at 7708C and completely thawed at 378C before use. If commercial reference preparations are used, they should be suitably calibrated; some have shown signi¢cant deviations from the International Standard in their potency estimates. 58 If commercial plasma is used, it is advisable to select preparations with good optical clarity wherever possible. In order to provide reference materials for widespread use, lyophilization is required to prevent deterioration of ¢brinogen. Reference plasma should not be turbid, as this creates practical problems with the calibration of optical coagulometers for clotting rate assays. 38 Reference ranges should be established in each laboratory, using at least 40 healthy normal subjects, covering a wide age range and both sexes. 4 Blood samples from patients should not be used; even if they are free from any major illness, it is likely that they will be stressed or may have an acute-phase reaction, which may skew the distribution of values. 13 
Quality control Internal quality control
An internal quality control (QC) sample, with a normal ¢brinogen concentration, should be analysed with each group of ¢brinogen determinations (or at intervals of 2-3 h for continuous processing systems). A QC sample with reduced or raised ¢brinogen may be useful depending on the purpose for which ¢brinogen assays are being performed, or if unexpected results are obtained for test samples. A written record of internal QC results should be maintained to include the result, time of analysis and reagent batch/lot numbers. It is useful to maintain a cumulative record, preferably as a graph (e.g. Levy-Jennings plots applying Westgard rules) because this can identify any gradual drift in QC results, which could indicate that the method is moving out of control. If a QC result lies outside acceptable limits (frequently provided by manufacturers as a target range) then patient testing must be suspended until the problem has been identi-¢ed and resolved. 13 
External quality assessment
It is essential for all laboratories to participate in an accredited external quality assessment scheme and investigate any evidence of local problems. For participants in larger groups, it may be possible to identify methodological bias related to particular components of the assay (such as reference plasma or source of reagent) and these should be taken into account when selecting a suitably standardized technique.
In the UK, external quality assessment is performed by the National External Quality Assurance Scheme (NEQAS) for Blood Coagulation. In a survey during 2000, 292 participants used a clotting rate assay, 211a PT-derived assay and 24 another type of assay. As discussed above ('Introduction'), signi¢cantly lower median ¢brinogen assays were observed with the clotting rate assay compared with the PT-derived assay. 61 Similar national external quality assessment programmes are performed in other countries, e.g. by the American College of Pathologists in the US.
Biological variation and reference intervals
The variation of ¢brinogen concentrations within the same normal subject was around1.00 g/L in a study of 14 normal subjects over a three-year period, although in some of the subjects ¢brinogen concentrations varied by more than 2.5 g/L. 62 This must be taken into account when ¢brinogen is being considered as a risk factor for ischaemic heart disease.
The upper half of Box 1 lists some physiological and lifestyle factors in£uencing plasma ¢brinogen concentrations. The e¡ects of age, female sex and smoking habit on plasma ¢brinogen reference intervals were illustrated in a random sample of the UK population aged 25-74 years, assayed by the clotting rate assay, standardized with the First International Fibrinogen Standard. 4, 7 These results are consistent with those of previous studies. 52 It is possible that the consistent ¢nding of higher clottable ¢brinogen concentrations in women compared with men may be partly explained by the lower haematocrit in women, which results in less dilution of plasma when blood is anticoagulated with trisodium citrate. When plasma ¢brinogen was assayed by a heat precipitation assay in whole blood anticoagulated with dry dipotassium edetate (hence no dilution of plasma), no sex di¡erence was observed. 51, 52 Safety Routine safety procedures for working with human plasma samples, standards or concentrates should be observed during plasma ¢brinogen assays. These include: careful use and disposal of sample tubes, vials, bottles and contents; wearing of protective gloves (especially over broken skin); caution to avoid cuts when handling sample tubes, vials and bottles; and avoiding the generation of aerosols.
Throughput
Automated clotting rate, ELISA or immunonephelometric assays can be performed on up to 200 test plasma samples per 7-h working session. For manual assays, throughput is lower (by about one order of magnitude).
Cost
Current reagent costs for automated clotting rate, ELISA or immunonephelometric assays are about »1 per test sample in the UK. PT-derived assays are much cheaper in terms of reagent costs (currently about 50 p per test sample for PT and PT-derived ¢brinogen in the UK); however their disadvantages should also be considered (see 'Introduction'). Laboratory sta¡ costs are proportional to throughput (see above). Equipment costs for automated assays vary with the cost of coagulometers and nephelometers (typical current cost in UK »10-30K), other assays performed on such equipment, and service costs.
Conclusion
Total clottable ¢brinogen assays remain the de¢nitive and reference method for plasma ¢brinogen assays, including ¢brinogen standards. They are timeconsuming and are rarely required in clinical practice.
Clotting rate assays 13, 20, 21 remain the routine method of choice for investigation, monitoring and treatment of bleeding disorders associated with low plasma ¢brinogen concentrations. They are appropriately sited in haematology or haemostasis laboratories, with facilities for further relevant investigations and expert advice from consultant haematologists on appropriate management. They have also been used in the majority of studies investigating increasing ¢brinogen concentrations as a cardiovascular risk factor.
Prothrombin-time derived assays are currently popular in haematology laboratories, because they are less expensive and come 'free' with PT assays. However, their results vary widely with analysers and reagents, show discrepancies with clotting rate assays for both low and normal plasma ¢brinogen samples, and at present are not recommended for routine clinical use. 13 Immunoassays (RID, ELISA or nephelometric) are useful in (a) di¡erentiating hypo¢brinogenaemia from dys¢brinogenaemia, and (b) assessment of cardiovascular risk and acute-phase reactions. Unlike clottable ¢brinogen assays, they can be performed in dipotassium edetate-anticoagulated samples.
